Dr Matthew Galsky speaks to ecancer about results from the phase 3 KEYNOTE-B15/EV-304 trial.

The results show that perioperative enfortumab vedotin plus pembrolizumab significantly improves outcomes in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy.

Compared with standard neoadjuvant gemcitabine plus cisplatin, the combination achieved higher pathologic complete response rates (55.8% vs 32.5%) and significantly improved event-free survival (HR 0.53) and overall survival (HR 0.65).

The safety profile was consistent with previous experience. These findings support enfortumab vedotin plus pembrolizumab as a promising perioperative treatment strategy for MIBC.